GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Biomerica Inc (NAS:BMRA) » Definitions » EV-to-EBIT

Biomerica (Biomerica) EV-to-EBIT

: -1.27 (As of Today)
View and export this data going back to 1978. Start your Free Trial

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Biomerica's Enterprise Value is $8.50 Mil. Biomerica's EBIT for the trailing twelve months (TTM) ended in Feb. 2024 was $-6.68 Mil. Therefore, Biomerica's EV-to-EBIT for today is -1.27.

The historical rank and industry rank for Biomerica's EV-to-EBIT or its related term are showing as below:

BMRA' s EV-to-EBIT Range Over the Past 10 Years
Min: -42.62   Med: -11   Max: 142.4
Current: -1.27

During the past 13 years, the highest EV-to-EBIT of Biomerica was 142.40. The lowest was -42.62. And the median was -11.00.

BMRA's EV-to-EBIT is ranked worse than
100% of 462 companies
in the Medical Devices & Instruments industry
Industry Median: 19.24 vs BMRA: -1.27

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Biomerica's Enterprise Value for the quarter that ended in Feb. 2024 was $16.07 Mil. Biomerica's EBIT for the trailing twelve months (TTM) ended in Feb. 2024 was $-6.68 Mil. Biomerica's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Feb. 2024 was -41.55%.


Biomerica EV-to-EBIT Historical Data

The historical data trend for Biomerica's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomerica Annual Data
Trend May14 May15 May16 May17 May18 May19 May20 May21 May22 May23
EV-to-EBIT
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.90 -25.89 -5.70 -8.93 -1.99

Biomerica Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
EV-to-EBIT Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.80 -1.99 -2.28 -1.49 -

Competitive Comparison

For the Medical Devices subindustry, Biomerica's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biomerica EV-to-EBIT Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Biomerica's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Biomerica's EV-to-EBIT falls into.



Biomerica EV-to-EBIT Calculation

Biomerica's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=8.496/-6.676
=-1.27

Biomerica's current Enterprise Value is $8.50 Mil.
Biomerica's EBIT for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.68 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biomerica  (NAS:BMRA) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Biomerica's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Feb. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Feb. 2024 ) =EBIT / Enterprise Value (Q: Feb. 2024 )
=-6.676/16.06584
=-41.55 %

Biomerica's Enterprise Value for the quarter that ended in Feb. 2024 was $16.07 Mil.
Biomerica's EBIT for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.68 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biomerica EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Biomerica's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomerica (Biomerica) Business Description

Traded in Other Exchanges
N/A
Address
17571 Von Karman Avenue, Irvine, CA, USA, 92614
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates in one segment namely, the design, development, marketing and sales of diagnostic kits. The majority of the company's revenue is earned from the Europe market.
Executives
John P. Kenny director 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Zacharys Irani director, officer: Cheif Executive Officer 17571 VON KARMAN AVE., IRVINE CA 92614
Gary Lu officer: Chief Financial Officer 12136 AHERN CT, TUSTIN CA 92782
Allen Barbieri director
Catherine Coste director 966 OCHO RIOS DR, DANVILLE CA 94526
David Moatazedi director C/O OBALON THERAPEUTICS, INC., 5421 AVENIDA ENCINAS, SUITE F, CARLSBAD CA 92008
Steven Sloan officer: Chief Financial Officer 114 TERRAPIN, IRVINE CA 92618
Mark A Sirgo director C/O BIODELIVERY SCIENCES INTERNATIONAL, 801 CORPORATE CENTER DRIVE -SUITE 210, RALEIGH NC 27607
Francis Cano director 11 ACORN LANE, LOS ALTOS CA 94022
Francis E Capitanio officer: President-diagnostics 1533 MONROVIA AVENUE, NEWPORT BEACH CA 92663
Janet Moore director, 10 percent owner, officer: Secretary 1533 MUNROVIA AVE, NEWPORT BEACH CA 92663
Jane Emerson director 1533 MONROVIA AVE, NEWPORT BEACH CA 92663
William Snider other: Greater than 5% holder 4800 MONTGOMERY LANE, SUITE 230, BETHESDA MD 20814
Broadoak Fund The other: Greater than 5% holder 7201 WISCONSIN AVE. #630, BETHESDA MD 20814
John Roehm director 1533 MONROVIA AVE., NEWPORT BEACH CA 92663

Biomerica (Biomerica) Headlines

From GuruFocus

Biomerica Reports Fiscal 2022 Year End Results

By Ds*** Ds*** 08-29-2022

Biomerica to Participate at BTIG Biotech Conference

By GuruFocusNews GuruFocusNews 07-03-2022